Pascal Soriot, AstraZeneca CEO (Chris Ratcliffe/Bloomberg via Getty Images)
Buyout buzz: Is AstraZeneca hunting a micro-M&A deal on Nasdaq?
A couple of weeks after being told by the powers that be at Nasdaq that it will need to get its battered share price out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
